New hypertension pill VB19055 enters first human safety trial

NCT ID NCT07254481

Recruiting now Disease control Sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new tablet called VB19055 in 86 healthy Chinese adults to see if it is safe and how the body processes it. Participants will receive either the drug or a placebo. The goal is to gather initial safety data before testing in people with high blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VB19055
What this could lead to: If successful, this could lead to a new medication option for controlling high blood pressure.
What could go wrong: This is an early Phase 1 trial in healthy volunteers, not patients. It primarily checks safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

Hangzhou First People's Hospital
RECRUITING

Hangzhou, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
NOT_YET_RECRUITING

Shanghai, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.